Cantor Fitzgerald Forecasts Strong Price Appreciation for Nuvalent (NASDAQ:NUVL) Stock

Nuvalent (NASDAQ:NUVL) had its price target upped by stock analysts at Cantor Fitzgerald from $135.00 to $140.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 37.32% from the company’s current price.

A number of other equities research analysts also recently weighed in on NUVL. Robert W. Baird boosted their price objective on shares of Nuvalent from $112.00 to $158.00 and gave the company an “outperform” rating in a research report on Tuesday, November 18th. Guggenheim upped their target price on Nuvalent from $125.00 to $155.00 and gave the company a “buy” rating in a report on Tuesday, November 18th. Barclays set a $152.00 price target on Nuvalent in a research report on Monday, November 17th. JPMorgan Chase & Co. reduced their price objective on Nuvalent from $147.00 to $145.00 and set an “overweight” rating for the company in a research report on Friday, December 19th. Finally, Stifel Nicolaus upped their price objective on Nuvalent from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Fifteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $138.67.

Nuvalent Stock Performance

NASDAQ:NUVL opened at $101.95 on Friday. The stock has a market cap of $7.41 billion, a price-to-earnings ratio of -17.43 and a beta of 1.32. Nuvalent has a one year low of $55.53 and a one year high of $113.01. The business’s 50-day simple moving average is $103.49 and its 200 day simple moving average is $95.18.

Insider Activity at Nuvalent

In other news, insider Christopher Durant Turner sold 4,236 shares of Nuvalent stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $97.32, for a total value of $412,247.52. Following the transaction, the insider owned 58,311 shares of the company’s stock, valued at $5,674,826.52. The trade was a 6.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO James Richard Porter sold 17,890 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $97.32, for a total value of $1,741,054.80. Following the completion of the transaction, the chief executive officer directly owned 288,172 shares in the company, valued at $28,044,899.04. This represents a 5.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 76,463 shares of company stock worth $7,722,489. Company insiders own 10.20% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. AQR Capital Management LLC increased its holdings in shares of Nuvalent by 64.8% in the 1st quarter. AQR Capital Management LLC now owns 9,874 shares of the company’s stock valued at $700,000 after purchasing an additional 3,881 shares during the period. Goldman Sachs Group Inc. grew its position in Nuvalent by 54.4% during the first quarter. Goldman Sachs Group Inc. now owns 453,620 shares of the company’s stock valued at $32,171,000 after purchasing an additional 159,873 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Nuvalent by 8.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 149,941 shares of the company’s stock valued at $10,634,000 after buying an additional 12,123 shares during the period. Intech Investment Management LLC increased its stake in Nuvalent by 28.7% in the 1st quarter. Intech Investment Management LLC now owns 19,262 shares of the company’s stock valued at $1,366,000 after buying an additional 4,293 shares during the period. Finally, CWM LLC lifted its position in Nuvalent by 253.8% in the 2nd quarter. CWM LLC now owns 1,486 shares of the company’s stock worth $113,000 after buying an additional 1,066 shares in the last quarter. 97.26% of the stock is owned by institutional investors and hedge funds.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.